Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alleviate-HF-1 Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04583527
Recruitment Status : Completed
First Posted : October 12, 2020
Last Update Posted : July 27, 2022
Sponsor:
Information provided by (Responsible Party):
Alleviant Medical, Inc.

Brief Summary:
Patients with heart failure and preserved left ventricular ejection fraction (HFpEF, EF ≥ 50%) or mid-range left ventricular ejection fraction (HFmrEF, 40% < EF < 50%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using clinical, echocardiographic, and invasive hemodynamic data.

Condition or disease Intervention/treatment Phase
Heart Failure Device: ALV1 System Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Safety and Feasibility of a Percutaneously Created Interatrial Shunt to Alleviate Heart Failure Symptoms in Patients With Chronic Heart Failure and Preserved or Mid-Range Left Ventricular Ejection Fraction
Actual Study Start Date : August 11, 2020
Actual Primary Completion Date : August 16, 2021
Actual Study Completion Date : August 16, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure


Intervention Details:
  • Device: ALV1 System
    The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.


Primary Outcome Measures :
  1. The composite incidence of one or more of the following through the 1-month follow-up visit: major adverse cardiac, cerebrovascular and thromboembolic events. [ Time Frame: At one month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Documented history of NYHA Class II, Class III or ambulatory Class IV at the screening visit.
  2. History of at least one hospitalization for treatment of heart failure within the past 12 months.
  3. LVEF greater than 40% as measured by the study-specific transthoracic echocardiography.
  4. Echocardiographic evidence of diastolic dysfunction documented by one or more of the following as measured by the study-specific transthoracic echocardiography protocol performed during screening:

    • LA diameter greater than 4 cm
    • LA volume index greater than 28 mL
    • Lateral e' less than 10 cm/s
    • Septal e' less than 8 cm/s
    • Lateral E/e' greater than 10
    • Septal E/e' greater than 15
  5. Elevated left atrial pressure WITH a gradient compared to right atrial pressure (RAP) documented by:

(1) end-expiratory PCWP at peak supine cycle ergometer exercise greater than or equa. to 25 mmHg AND (2) PCWP greater than RAP by greater than or equal to 5 mmHg, OR greater than or equal to 10 mmHg increase of end-expiratory PCWP at peak supine cycle ergometer exercise compared to resting PCWP AND PCWP greater than RAP by greater than or equal to 5 mmHg.

Exclusion Criteria:

  1. Presence of advanced heart failure defined as one or more of the following:

    • ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF.
    • Cardiac index less than 2.0 L/min/m2.
    • Patient is on the cardiac transplant waiting list.
    • Inotropic infusion (continuous or intermittent) for EF less than 40% within the past 6 months.
  2. Presence of moderate or worse valve disease, defined as one or more of the following:

    • Moderate or worse mitral valve regurgitation or moderate or worse mitral stenosis.
    • Moderate or worse tricuspid valve regurgitation.
    • Moderate or worse aortic valve disease defined as moderate or worse AS or AI.
  3. . Presence of chronic pulmonary disease defined by one or more of the following:

    • Requirement for continuous home oxygen use.
    • Hospitalization within the past 12 months for treatment of pulmonary disease.
    • Significant chronic pulmonary disease defined as FEV1 less than 50%.
  4. Documented as currently requiring dialysis or estimated GFR less than 25ml/min/1.73m2
  5. 6-minute walk distance less than 50 m or greater than 450 m performed during screening.
  6. Documented atrial fibrillation with ventricular rate greater than 100 BPM at screening.
  7. Presence of moderate or worse right heart dysfunction OR RV dysfunction defined as TAPSE less than 14 mm or RVFAC less than or equal to 30%
  8. Presence of pulmonary hypertension with PASP greater than or equal to 70 mmHg OR PVR greater than 4 Wood units.
  9. Presence of anatomic anomaly that precludes creation of interatrial shunt (including patent foramen ovale, atrial septal defect, target septal thickness greater than 3 mm)
  10. SBP greater than 170 mmHg at screening.
  11. Documented left ventricular end diastolic diameter greater than 6 cm.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04583527


Locations
Layout table for location information
Georgia
Tbilisi Heart & Vascular
Tbilisi, Georgia
Sponsors and Collaborators
Alleviant Medical, Inc.
Layout table for additonal information
Responsible Party: Alleviant Medical, Inc.
ClinicalTrials.gov Identifier: NCT04583527    
Other Study ID Numbers: CIP-0001
First Posted: October 12, 2020    Key Record Dates
Last Update Posted: July 27, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases